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http://www.biomedcentral.com/1471-2369/13/152RESEARCH ARTICLE Open AccessWho should be prioritized for renal
transplantation?: Analysis of key stakeholder
preferences using discrete choice experiments
Michael D Clark1*, Dennis Leech2, Anil Gumber3, Domenico Moro4, Ala Szczepura5, Nick West6 and Robert Higgins6Abstract
Background: Policies for allocating deceased donor kidneys have recently shifted from allocation based on Human
Leucocyte Antigen (HLA) tissue matching in the UK and USA. Newer allocation algorithms incorporate waiting time
as a primary factor, and in the UK, young adults are also favoured. However, there is little contemporary UK
research on the views of stakeholders in the transplant process to inform future allocation policy. This research
project aimed to address this issue.
Methods: Discrete Choice Experiment (DCE) questionnaires were used to establish priorities for kidney
transplantation among different stakeholder groups in the UK. Questionnaires were targeted at patients, carers,
donors / relatives of deceased donors, and healthcare professionals. Attributes considered included: waiting time;
donor-recipient HLA match; whether a recipient had dependents; diseases affecting life expectancy; and diseases
affecting quality of life.
Results: Responses were obtained from 908 patients (including 98 ethnic minorities); 41 carers; 48 donors /
relatives of deceased donors; and 113 healthcare professionals. The patient group demonstrated statistically
different preferences for every attribute (i.e. significantly different from zero) so implying that changes in given
attributes affected preferences, except when prioritizing those with no rather than moderate diseases affecting
quality of life. The attributes valued highly related to waiting time, tissue match, prioritizing those with dependents,
and prioritizing those with moderate rather than severe diseases affecting life expectancy. Some preferences
differed between healthcare professionals and patients, and ethnic minority and non-ethnic minority patients. Only
non-ethnic minority patients and healthcare professionals clearly prioritized those with better tissue matches.
Conclusions: Our econometric results are broadly supportive of the 2006 shift in UK transplant policy which
emphasized prioritizing the young and long waiters. However, our findings suggest the need for a further review in
the light of observed differences in preferences amongst ethnic minorities, and also because those with
dependents may be a further priority.
Keywords: Renal transplant, Allocation, Choice experiment, StakeholderBackground
In the United Kingdom (UK) in January 2011 there were
6,610 patients awaiting renal transplantation (a figure
which had risen by 8% annually since 2004). In the previ-
ous year (2009–10), only 1,482 patients received deceased
donor transplants, and 1,038 received live donor trans-
plants [1]. A growing imbalance between demand and* Correspondence: Michael.Clark@warwick.ac.uk
1Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
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reproduction in any medium, provided the orsupply led to the Organ Donation Taskforce Report in
2008 [2] outlining strategies to increase UK organ supply
by 50% within 5 years. However, despite the resultant in-
crease in organ supply, demand still continues to outstrip
supply. So criteria remain necessary to allocate the limited
supply of kidneys which are available for transplantation.
A transplant policy based on efficiency criteria would
require that organs be transplanted to patients deriving
greatest health benefit. Criteria to address equity of access
may conflict with efficiency ones. Patients waiting a longd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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even if someone else, who has not waited as long, would
obtain greater health benefits from transplantation. In
2006, UK transplant policy was re-appraised. The previous
policy was thought to disadvantage those with less com-
mon tissue types and blood groups, especially ethnic mi-
norities. This population is also at higher risk of kidney
disease [3]. African Caribbeans and Asians have a 3–4
times greater risk of end stage renal disease [2] related to a
higher prevalence of type 2 diabetes [4]. Increased risk of
renal disease in these groups is also associated with
increased risk of co-morbidities such as hypertension [5]
and cardiovascular disease [6]. Moreover, ethnic minorities
donate fewer organs [6], so individual patients are less
likely to obtain closely matched transplants.
The 2006 re-appraisal led to reduced priority being
attached to HLA matching in the UK, and allowed consid-
eration of other criteria [7]. The resulting guidelines [8]
suggested more priority should be given to long waiters
and paediatric and younger adult recipients. Research
from the USA and Australia had, indicated such changes
would be acceptable to professionals and patients [9,10].
Although there was some excellent UK research to inform
prioritization [11], this research did not adopt DCE meth-
odology, unlike ours.
In this analysis we have used Discrete Choice Experi-
ments (DCEs) in order to establish respondent’s valuation
of different kidney transplant allocation criteria, and how
they might trade-off gains in relation to one transplant al-
location criterion, for losses in relation to another trans-
plant allocation criterion. DCEs involve the application of
a stated preference technique in order to establish a
respondent’s valuation of attributes or characteristics of a
good or service or health state. DCEs are increasingly
being used to address priority setting issues in healthcare,
both in primary care [12], and secondary care [13,14].
Some DCE research has been published on general trans-
plantation issues, including assessing factors influencing
willingness to donate body parts [15] and a DCE to estab-
lish UK priorities for liver transplantation [16,17]. In renal
transplantation, the first DCE findings internationally ema-
nated from our study conducted in the UK [18]. This pub-
lication focused solely on assessing whether patient
preferences varied by ethnicity and gender. More recently,
DCE research has been undertaken in Canada relating to
patient and healthcare professional preferences for chronic
kidney disease (CKD) care more generally (although not
specifically focused on kidney transplantation) [19].
The current paper provides more extensive evidence on
the preferences of various stakeholder groups alongside
those of patients than our earlier paper [18]. These groups
include patients, renal healthcare professionals, renal
carers, and live donors / relatives of deceased donors. Un-
like the general public (who may lack personal experienceof renal disease) all these ‘expert’ stakeholder groups will
have a direct interest in priorities for kidney transplant al-
location, either because they have renal disease themselves
(patients) or care for those with such a disease (renal
carers/renal healthcare professionals). Moreover, live do-
nors or relatives of deceased donors are concerned to
ensure kidneys are appropriately allocated. Therefore re-
search to improve understanding of the preferences of
these different stakeholder groups should help inform the
policy debate about transplantation.
Methods
Overview
This Discrete Choice Experiment (DCE) study assumed
that respondents’ valuations of different kidney transplant
allocation criteria can be decomposed into component
parts known as attributes. The DCE involved respondents
making repeated hypothetical pairwise choices in which
they expressed their stated preferences about which of two
transplant recipients (differing in these pre-defined char-
acteristics or attributes) should receive a kidney. DCE
respondents’ trade-offs were established so that weightings
given to different recipient characteristics (attributes)
could be quantified. The pilot study for this research
began in 2005; the main study started in 2006 with final
data analysis completed during 2007–09. Ethical approval
was obtained from Warwickshire Local Research Ethics
Committee (reference number 05/Q2803/86).
Pilot exercise
Although some DCEs have been undertaken without
undertaking a pilot exercise first, the benefits of initial
piloting and analysis of pilot data econometrically are
considerable. We therefore undertook a rigorous pilot
exercise using both qualitative and quantitative methods.
For full details see Additional file 1. Attributes tested in
the pilot included waiting time, tissue match, employ-
ment status, number of dependents, recipient age and
various diseases affecting recipient health. Attributes and
level selection was mainly informed by discussions with
clinicians. Given the number of attributes and levels
selected, we needed to design a DCE questionnaire
which used a limited number of different choice scenar-
ios, which would be sufficient to infer choice informa-
tion. However, we also invited pilot respondents to
suggest other possible attributes and rank them in order
of priority (alongside those already in the questionnaire).
Attributes tested in the pilot included waiting time, tis-
sue match, employment status, number of dependents,
recipient age, patient compliance, whether illness could
be regarded as ‘self-inflicted’ and various diseases (co-
morbidities) affecting recipient health. Early during the
pilot some respondents expressed disquiet about the em-
ployment attribute, arguing it represented unwarranted
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because of illness. We therefore asked all respondents
whether this should be included. Most respondents said
‘no’, so this was omitted. We used the computer package
SPEED (software designed to establish choice sets for
DCEs [20]) for the pilot DCE to generate such an or-
thogonal main effects design. We paired choices gener-
ated by SPEED to minimize attribute overlap and level
imbalance [21]. The pilot exercise analysed 60 responses
to establish appropriate attributes and levels for use in
the final DCE questionnaire.
Identifying attributes and levels for final DCE
The pilot exercise analyzed 60 responses to ascertain attri-
butes and levels for the final DCE using Random Effects
Probit. All the attributes (with the exception of the em-
ployment status attribute) proved significant at the 5%
level (i.e. implying that the attribute would affect a respon-
dent’s choice of who to prioritize for kidney transplant).
Final pilot findings from attribute rankings indicated that
the employment status attribute was far from highly
ranked and it was therefore removed. The following inclu-
sions were warranted, with some limited changes. Respon-
dents thought people with dependents ought to be
prioritized, but most considered adult as well as child
dependents should be included, so this attribute was
amended to include adults. Age was considered relevant,
but the recipient age ceiling was reduced to 65 because
clinicians indicated that transplantation was less likely
amongst over 65s. Although highly ranked separately,
when combined the life expectancy and other recipient
diseases (non-CKD co-morbidities) attributes resulted in
unrealistic DCE scenarios. For example, one pairwise
choice resulted in respondents choosing between a 70 year
old with severe arthritis with 12 years life expectancy, and
a 45 year old without co-morbidities with a shorter life ex-
pectancy. Such a comparison did not make sense since a
45 year old without co-morbidities would be expected to
have a longer life expectancy. So, the life expectancy attri-
bute was replaced with one indicating whether a potential
recipient had diseases predominantly affecting life expect-
ancy. This provided more realistic scenarios and improved
DCE design.
Other attributes highly ranked in the pilot exercise
included ‘patient compliance’ and whether illness was
‘self-inflicted’. However, advice from medical profes-
sionals highlighted the fact that unlike ‘liver transplant-
ation’ renal transplantation was rarely required because
of alcohol or drug misuse, so this was not a particularly
relevant consideration to underpin attributes and levels
for the DCE. Also patients who are thought likely to
abuse their bodies or be non-compliant would not be
transplanted. On this basis, it was decided to exclude
this attribute.Table 1 lists the final attributes and levels selected for
use in the DCE questionnaires. Copies of the question-
naires are provided in Additional file 2.
The pilot questionnaire contained an explanatory pre-
amble which described the attributes and levels included.
Transplant survival rates were presented from UK
Transplant and it was explained that these were con-
tingent upon donor/recipient tissue match. Although
transplant survival rates were available for longer time
horizons, we wanted to avoid information overload and
therefore only presented 12 month survival rates. The
pilot confirmed that explanatory information was easy to
understand.
Final Discrete Choice Experiment (DCE)
We used a binary dependent variable model in order to
force a choice. This is because, in reality, transplant
decisions have to be made and medical professionals
face a forced choice when allocating kidneys because of
donor scarcity. Moreover, pilot interviews revealed that
many respondents felt uncomfortable with deciding who
to transplant. Therefore, it was judged that including a
‘cannot decide’ option might have triggered such a re-
sponse from people who in reality were not indifferent.
An alternative would have been to allow choices be-
tween more than 2 potential recipients using a multi-
nomial model, or to have more attributes and levels; but
this would have complicated decision making [22].
Moreover, since many renal patients suffer from fatigue
we wanted to avoid complicated decisions, because when
complexity increases there is evidence that respondents
may be more inclined to use simplifying heuristics [23]
compromising response reliability. Copies of the final
DCE questionnaires are provided in Additional file 2.
The final DCE design was again an Orthogonal Main
Effects Plan (OMEP) design involving independent valu-
ation of attributes. To ensure a perfectly orthogonal de-
sign and improve efficiency we used an OMEP design
supplied by leading DCE designers [24] rather than
SPEED as used in the pilot exercise. We also blocked 18
choices into 2 blocks of 9 questions (versions A and B)
to reduce respondent fatigue and limit the patient ques-
tionnaire to 10 pages. Respondents were asked to choose
between transplanting patient A with particular attribute
levels or patient B with different levels (see Additional
file 2 for examples).
Questionnaire distribution
We included an information leaflet and freepost envelope
in the National Kidney Federation’s newsletter ‘Kidney
Life’ (circulation c.20,000). The leaflet invited patients,
carers, donors or healthcare professionals to request a
DCE questionnaire. Individuals who replied were sent a
questionnaire, along with a covering letter, consent form,
Table 1 Details of final attributes and levels used for Discrete Choice Experiment (DCE) questions
Attribute Variable name Levels Interpretation of coefficients
Time spent awaiting
transplantation
Wait 1 month, 2 years, and 10 years. Indirect utility of each 1 year reduction in
transplant recipient waiting time.
Tissue type matching. Tiss Non-favourable match: 86% average kidney survival rate
post-transplant.
Indirect utility of prioritizing people for each
1% improvement in kidney survival.
Favourable match: 89% average kidney survival rate post-
transplant.
Perfect match: 90% average kidney survival rate post-
transplant.
How many child or
adult dependents
recipients have
Dep None, 1, or 4 dependents. Indirect utility of each additional dependent.
Recipient age Age 20 years, 45 years, and 65 years Indirect utility for each 1 year reduction in
recipient age.
Diseases
predominantly
affecting life
expectancy
dis1 No disease affecting life expectancy (other than Kidney
disease) vs. moderate disease (uncontrolled hypertension
or obesity) & Kidney disease.
Indirect utility of having no rather than
moderate disease predominantly affecting life
expectancy.
dis2 Moderate disease (uncontrolled hypertension or obesity)
affecting life expectancy vs. severe disease (heart attack,
stroke, or diabetes with complications).
Indirect utility of having moderate disease
rather than severe disease predominantly
affecting life expectancy.
Diseases
predominantly
affecting quality of
life
ill1 No disease affecting quality of life (other than Kidney
disease) vs. moderate disease (mild asthma).
Indirect utility of having no disease rather
than a moderate disease predominantly
affecting quality of life.
ill2 Moderate disease (mild asthma) affecting quality of life vs.
severe disease (severe arthritis).
Indirect utility of having a moderate disease
rather than a severe disease predominantly
affecting quality of life.
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naire. Individuals who did not return a questionnaire were
not contacted again. Questionnaires were also posted dir-
ectly to members of the British Organ Donor Society,
healthcare professionals listed in the UK Transplant ser-
vice directory, and to non-transplanting units with trans-
plant coordinators or transplant physicians. Relatives of
deceased donors were targeted via the British Organ
Donation Society (BODY). To increase ethnic minority
responses we provided questionnaires in a person’s pre-
ferred language. A reputable translation organization was
used to translate questionnaires in Punjabi, Hindi, Bengali,
Gujarati and Urdu. A bilingual researcher administered
the questionnaires upon non-English speaking patients
and checked the questionnaire’s translation accuracy. We
obtained additional responses from Ealing NHS Trust,
and from University Hospital, Coventry using transla-
ted questionnaires to increase levels of ethnic minority
participation.
Assessing the representativeness of respondent sample
In order to assess representativeness, we used UK Renal
Registry data (when available); figures were extracted for
transplant success rates. Other relevant patient data
were not available i.e. patients with failed transplant,
awaiting a transplant, on dialysis, or with kidney disease
not requiring dialysis. UK Renal Registry data also does
not record detailed ethnicity information for some sub-
groups of respondents, so detailed patient data is not
available for all sub-groups.Econometric / statistical analysis models
Two models were used for analysis (for full details refer
to Additional file 3). Random Effects probit (model 1
and 2) was used to establish different stakeholder prefer-
ences. Model 1 used a series of dummy variables to
ascertain whether preferences for specific attributes dif-
fered amongst carers, donors/relatives of deceased
donors, and healthcare professionals compared with the
patient respondents group.
Model 2 compared the preferences of ethnic minority
and white majority patients. Again a series of dummy
variables were used to establish whether preferences dif-
fered between ethnic minority and other patients for
specific attributes.
Marginal Rate of Substitution (MRS)
Data were analysed in terms of a measure of marginal
rate of substitution (MRS) which related differences in
other attributes (potential transplant priority criteria) to
waiting time for renal transplants. Analysis examined
whether differences in MRS were statistically significant
between stakeholder groups for specific attributes (using
Wald tests). We also used the Delta method [25] with
command ‘nlcom’ in STATA to estimate 95% confidence
intervals. Full details of the approach used to derive
MRS are provided in Additional file 4 (Table 1). Wald
tests using ‘testnl’ in STATA were used to establish
whether MRS differed significantly between groups;
comparing patients with carers, donors and healthcare
professionals (model 1); and ethnic minority patients vs.
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lish whether preferences for tissue matching differed be-
tween ethnic and non-ethnic minorities (model 2), the
null hypothesis was that tissue match MRS was identical
for both (p ≤ 0.05 indicated a difference at the 5% level).
Results
Sample characteristics
Table 2 presents respondent characteristics. We obtained
908 patient responses; 18 additional responses from Ealing
NHS Trust and 5 from University Hospital, Coventry were
obtained using translated questionnaires. UK Renal Regis-
try data [26,27] was used to assess patient sample repre-
sentativeness. 508/908 patient respondents (55.9%) were
male, 397/908 (43.7%) were female, and 3/908 (0.3%) notTable 2 Details of characteristics of questionnaire
respondent samples
Patients
(n = 908)
Carers
(n=41)
Donors
(n =48)
Healthcare
workers
(n=113)
AGE
Mean age 54.88 years 52.37
years
54.67
years
43.23 years
GENDER
Male 508 (55.9%) 10 (24.4%) 14 (29.2%) 51 (45.1%)
Female 397 (43.7%) 31 (75.6%) 34 (70.8%) 61 (54.0%)
Not indicated 3 (0.3%) 0 (0%) 0 (0%) 1 (0.9%)
ETHNICITY
White (British) 799 (88%) 38 (92.7%) 44 (91.7%) 89 (78.8%)
White ethnic
minorities
27 (2.9%) 1 (2.4%) 1 (2.1%) 9 (8%)
Non-white
ethnicity
(excluding
Asians)
19 (2.1%) 1 (2.4%) 0 (0%) 2 (1.8%)
Non-white
ethnicity (Asians)
50 (5.5%) 1 (2.4%) 1 (2.1%) 9 (8%)
Not indicated 13 (1.4%) 0 (0%) 2 (4.2%) 4 (3.5%)
DEPENDENT
CHILDREN
0 755 (83.1%) 33 (80.5%) 36 (75%) 51 (45.1%)
1 72 (7.9%) 2 (4.9%) 5 (10.4%) 22 (19.5%)
2 49 (5.4%) 5 (12.2%) 2 (4.2%) 26 (23.0%)
3 12 (1.3%) 0 (0%) 3 (6.3%) 9 (8.0%)
> 3 7 (0.8%) 1 (2.4%) 1 (2.1%) 3 (2.7%)
Not indicated 13 (1.4%) 0 (0%) 1(2.1%) 2 (1.8%)
DEPENDENT
ADULTS
0 750 (82.6%) 16 (39.0%) 39 (81.2%) 98 (86.7%)
1 121 (13.3%) 17 (41.5% 6 (12.5%) 11 (9.7%)
2 17 (1.9%) 6 (14.6%) 2 (4.2%) 3 (2.7%)
> 2 8 (0.9%) 1 (2.4%) 0 (0%) 0 (0%)
Not indicated 12 (1.3%) 1 (2.4%) 1 (2.1%) 1 (0.9%)reported. Renal Registry data [26] similarly indicates a
slightly higher proportion of male than female patients
across age groups. The average patient age in the sample
was 54.9 years (median 57 years), coinciding with the
Renal Registry data median age (57.3 years) [27]. Of the
895/ 908 patients indicating ethnicity, 799/895 (89.3%)
were white British and 27/895 (3%) were other white back-
ground (e.g. Irish), giving a total of 92.3% white patients.
UK data [26] indicates that 79.7% of renal patients are
white. So white respondents are over-represented in our
survey. Overall, 69/895 (7.7%) patients indicating ethnicity
were non-white, compared with an expected 20.3% inci-
dence rate [26], and 50/69 of the non-white patients were
South Asians (5.6% of those indicating ethnicity) com-
pared to an anticipated 10.5% [26].
In terms of transplant history, the patient sample
comprised: 468/908 (51.5%) with successful transplants,
118/908 (13%) whose transplant had failed and 279/908
(30.7%) awaiting transplant (average wait 22.6 months).
Some patients whose transplant had failed also reported
they were ‘awaiting transplantation’. Of the remainder,
237/908 (26.3%) were undergoing dialysis without trans-
plantation and 57/908 (6.3%) had kidney disease not re-
quiring dialysis. Renal Registry data [27] indicates 46.9%
of patients have successful transplants (close to our
figure). There are no data for the other patient charac-
teristics. Amongst non-whites (including Asians) our
sample included 18/69 patients (26%) with successful
transplants and 10/69 (14.5%) whose transplant had
failed; 35/69 patients (50.7%) were awaiting a trans-
plant on dialysis (average wait: 21.45 months) and
3/69 (4.3%) had kidney disease not requiring dialysis.
These statistics cannot be compared with UK Renal
Registry data since ethnicity is not recorded for such
sub-groups [27]. However, a lower percentage figure for
transplant success and a higher figure for patients await-
ing transplants might be expected (ethnic minorities do-
nate fewer organs and transplants are less likely to be
closely matched).
Of the 48 donor respondents, 21 were live donors and 27
relatives of deceased donors. Healthcare professionals com-
prised: 9 renal surgeons, 37 renal physicians, 17 transplant
co-ordinators, 31 nurses, 9 clinical scientists, 1 GP, 1 diet-
ician, 1 network manager, 1 transplant scientist, 1 medical
student, 1 transplant immunologist, 1 tissue typer, 1 clinical
audit manager, 1 renal technologist and a pathologist.
Data analysis
Table 3 presents model 1 results including MRS 95% con-
fidence intervals (CIs). Variables are as listed in Table 1.
Coefficients are as indicated in Table 1. MRS in Table 3
indicates indirect utility values for changes in attributes (for
direction of change see Table 1) relative to values for priori-
tizing a recipient waiting an extra year for transplantation
Table 3 Model 1: results and MRS (i.e. utility value of other attributes expressed in terms of trade-off with 1 year
waiting time) for patients, carers, donors, and healthcare workers
Attribute Coefficient :
patients
Implied MRS
for patients
Coefficient : dummies for
the carer group
Implied MRS for
carers
Wald test p-values:
Carers vs. patients
Wait .0443** 1 -.0156 1
Tiss .0624** 1.41* am 0.76 p=0.0024
(1.08 / 1.74) (−1.42 / 2.93)
Dep .0635** 1.43* -.0585* 0.17 p<0.0001
(1.17 / 1.69) (−1.54 / 1.89)
Age .0069** 0.16* .0006 0.26 p=0.0750
(0.12 / 0.19) (−0.03 / 0.56 )
dis1 -.0004 −0.01 .1205 4.18 p=0.2965
(−1.03 / 1.01) (−3.25 / 11.62)
dis2 .6789** 15.32* -.1971 16.79* p<0.0001
(13.45 /
17.20)
(2.69 / 30.89)
ill1 -.1207** −2.73* .1130 −0.27 p=0.1236
(−1.45 / -4.00) (−9.55 / 9.01)
ill2 .1850** 4.18* -.0334 5.28 p=0.0910
(3.12 / 5.23) (−2.27 / 12.83)
Intercepts .1208** -.0034
Attribute Coefficient :
dummies for the
donor group
Implied MRS
for donors
Wald test p-
values: Donors vs.
patients
Coefficient : dummies for
the healthcare worker
group
Implied MRS for
healthcare
workers
Wald test p-values:
healthcare workers vs.
patients
Wait -.0086 1 -.0039 1
Tiss -.0667* −0.12 p<0.0001 -.0110 1.27* p=0.0027
(−1.62 / 1.38) (0.24 / 2.31)
Dep -.0468* 0.47 p<0.0001 -.0003 1.56* p=0.0017
(−0.79 / 1.73) (0.72 / 2.41)
Age -.0023 0.13 p=0.0067 .0127** 0.48* p=0.0300
(−0.05 / 0.31) (0.31 / 0.66)
dis1 .1508 4.22 p=0.1669 .1823** 4.50* p=0.0265
(−1.38 / 9.81) (1.09 / 7.91 )
dis2 -.2676* 11.54* p<0.0001 .1056 19.42* p<0.0001
(2.90 / 20.17) (12.71 / 26.14)
ill1 .0520 −1.93 p=0.2301 .0501 −1.75 p=0.1048
(−8.66 / 4.80) (−5.74 / 2.24)
ill2 .0245 5.87* p=0.1942 .1790* 9.01* p=0.9818
(0.18 / 11.57) (5.44 / 12.59 )
Intercepts -.112 .0844
*: Significant at 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates.
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mulae). In effect MRS indicates the rate at which the re-
spondent group in question is willing to trade-off gains in
relation to one criterion against losses in relation to another
(in this case the amount of time waiting). MRS in Table 4 is
expressed in terms of 1 or 5 year waiting times. Measures
of ‘goodness of fit’ for model 1 (Random Effects probit)
show that 63% of actual values are predicted by the model,
and McFadden's R2 = 0.1088. A likelihood ratio test for the
joint significance of the dummy variables has 27 degrees of
freedom with a critical value of 40.11, compared with
λ=71.90, so the dummy variables are jointly significant. The
tissue match coefficient (tiss) in Table 4 indicates the
impact of a 1% difference in 12 month kidney survival.
Difference in survival rate between a perfect vs. favourablematch is 1%, so the MRS figure of 1.41 (Table 3) also
appears in Table 4 for ‘Prioritizing perfect not non-
favourable tissue matches’. Table 4 indicates MRS for the
’Prioritizing someone with a favourable not non-favourable
match’ (1.41 × 3 [a 3% difference in kidney survival rate] =
4.23). It also shows how much respondents value other
changes in attributes compared to a 1 year wait (column 2).
Moreover 5 year MRS figures are presented in Table 4 (col-
umn 3). If waiting time increases 5 fold, MRS for a 5 year
wait is 1/5th of 1 year MRS. 95% CIs for 5 year MRS are
1/5th of 1 year. The CIs define the range within which MRS
figures must lie (to be 95% confident).
When interpreting results it might be expected that, in
general, transplant preferences would lie in certain di-
rections. On efficiency grounds improvements in kidney
Table 4 Model 1: MRS (i.e. utility value of other attributes expressed in terms of trade-off with 1 year or 5 year waiting
time) for patients, carers, donors and healthcare workers
Variable Patient trade-off
between variable & 1
year wait
Patient trade-off
between variable & 5
years wait
Carers trade-off between
variable & 1 year wait
Carers trade-off between
variable & 5 years wait
Prioritizing perfect not favourable
tissue matches
1.41* 0.28* 0.76 0.15
(1.08 / 1.74) (0.22 / 0.35) (−1.42 / 2.93) (−0.28 / 0.59)
Prioritizing favourable not non–
favourable tissue matches
4.23* 0.85* 2.27 0.45
(3.23 / 5.22) (0.65 / 1.05) (−4.25 / 8.80) (−0.85 / 1.76)
Prioritizing a recipient with
dependents – per extra
dependent
1.43* 0.29* 0.17 0.03
(1.17 / 1.69) (0.23 / 0.34) (−1.54 / 1.89) (−0.31 / 0.38)
prioritizing a younger recipient –
per year younger
0.16* 0.03** 0.26 0.05
(0.12 / 0.19) (0.02 / 0.04) (−0.03 / 0.56 ) (−.01 / 0.11)
Prioritizing those with ‘no’ not
‘moderate’ diseases affecting life
expectancy
−0.01 0.00 4.18 0.84
(−1.03 / 1.01) (−0.21 / 0.20) (−3.25 / 11.62) (−0.65 / 2.32)
Prioritizing those with moderate
not severe diseases affecting life
expectancy
15.32* 3.06* v16.79* 3.36*
(13.45 / 17.20) (2.69 / 3.44) (2.69 / 30.89) 0.54 / 6.18)
Prioritizing those with no not
moderate diseases affecting QoL
−2.73* −0.55* −0.27 −0.05
(−1.45 / -4.00) (−0.29 / -0.80) (−9.55 / 9.01) (−1.91 / 1.80)
Prioritizing those with moderate
not severe diseases affecting QoL
4.18* 0.84* 5.28 1.06
(3.12 / 5.23) (0.62 / 1.05) (−2.27 / 12.83) (−0.45 / 2.57)
Variable Donors trade-off
between variable & 1
year wait
Donors trade-off
between variable & 5
year wait
Healthcare workers trade-
off between variable & 1
year wait
Healthcare workers trade-
off between variable & 5
year wait
Prioritizing perfect not favourable
tissue matches
−0.12 −0.02 1.27* 0.25
(−1.62 / 1.38) (0.32 / 0.28) (0.24 / 2.31) (0.05 / 0.46)
Prioritizing favourable not non-
favourable tissue matches.
−0.36 −0.07 3.82* 0.76*
(−4.86 / 4.14) (−0.97/ 0.83) (0.72 / 6.93) (0.14 / 1.39)
Prioritizing a recipient with
dependents – per extra
dependent
0.47 0.09 1.56* 0.31*
(−0.79 / 1.73) (−0.16 / 0.35) (0.72 / 2.41) (0.14 / 0.48)
prioritizing a younger recipient –
per year younger
0.13 0.03 0.48* 0.10*
(−0.05 / 0.31) (−0.01 / 0.06) (0.31 / 0.66) (0.06 / 0.13)
Prioritizing those with no not
moderate diseases affecting life
expectancy
4.22 0.84 4.50* 0.90*
(−1.38 / 9.81) (−0.28 / 1.96) (1.09 / 7.91 ) (0.22 / 1.58)
Prioritizing those with moderate
not severe diseases affecting life
expectancy
11.54* 2.31* 19.42* 3.88*
(2.90 / 20.17) (0.58 / 4.03) (12.71 / 26.14) (2.54 / 5.23)
Prioritizing those with no not
moderate diseases affecting QoL
−1.93 −0.39 −1.75 −0.35
(−8.66 / 4.80) (−1.73 / 0.96) (−5.74 / 2.24) (−1.15 / 0.45)
Prioritizing those with moderate
not severe diseases affecting QoL
5.87* 1.17* 9.01* 1.80*
(0.18 / 11.57) (0.04 / 2.31) (5.44 / 12.59 ) (1.09 / 2.52)
*: Significant at 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates.
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dents should generally prefer transplants with the highest
chance of success. But, some stakeholder groups might not
exhibit this preference if there is a lack of organs closely
matching their own requirements. We might expect
respondents to prioritize those waiting longer for a trans-
plant on equity grounds, and therefore would anticipate a
positive coefficient on a one year reduction in waiting time.
It might also be considered that recipients with more
dependents should be prioritized because more people
would benefit from a recipient’s improved health. Incontrast, all other things being equal, one might expect
older patients to benefit less because they have a lower life
expectancy, so the coefficient on reductions in recipient age
would be expected to be positive. Finally, for efficiency rea-
sons respondents might prioritize more highly those with
fewer or no disease(s) affecting life expectancy over those
with moderate diseases.
Patients’ MRS figures (Table 4) suggest, all other things
being equal (ceteris paribus), that patients would prioritize
recipients with perfect over favourable tissue matches (tiss)
more than those waiting an extra year (1 year MRS =1.41,
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1.00). However, if a favourably matched patient were to
wait 5 years longer, they would be a higher priority than
the perfect match (MRS = 0.28) <1. Similarly, prioritizing
someone with a favourable not non-favourable match
(ceteris paribus) is valued more than prioritizing someone
waiting for 1 year (MRS = 4.23) as it exceeds 1, the utility
from a 1 year wait. But if a potential recipient waited 5
years longer, prioritizing the longest waiter is optimal
(MRS = 0.85) < 1.
Patients also prioritized someone with an extra de-
pendent more than waiting a year longer (MRS for
‘dep’=1.43). However, if a potential recipient waited 5 years
longer MRS = 0.29, for an extra dependent, so prioritizing
an extra dependent is a lower priority. Prioritizing a recipi-
ent who is 1 year younger is valued less than a 1 year or 5
year reduction in waiting time (‘age’ 1 year MRS = 0.16, 5
year = 0.03). Patients would also not prioritize those with
no vs. moderate diseases predominantly affecting life ex-
pectancy (‘dis 1’ is insignificant), but would prioritize (dis2)
those with moderate rather than severe diseases predomin-
antly affecting life expectancy highly (1 year MRS = 15.32;
5 year MRS = 3.06). Thus, someone with a moderate, not
severe, disease predominantly affecting life expectancy is
prioritized (MRS >1).
Paradoxically, for diseases predominantly affecting
quality of life, rather than life expectancy, patients prior-
itized those with moderate not no disease (‘ill1’ has a 1
year waiting time MRS of −2.73), perhaps because many
patients have moderate co-morbid diseases. However, 5
year MRS equals −0.55, so long waiters are a higher pri-
ority than those with moderate rather than no disease
affecting quality of life. Finally, patients prioritized those
with moderate rather than severe diseases predominantly
affecting quality of life (‘ill2’ 1 year MRS = 4.18; 5 year
MRS = 0.84). So, ceteris paribus, someone with moder-
ate not severe disease would be a higher priority than
someone waiting 1 year longer (MRS>1), but a lower
priority than someone waiting 5 years longer (MRS < 1).
Carer results (Tables 3 and 4) were compromised to
some extent by the smaller sample size (n=41), so MRS
was only significant for 1 variable - prioritizing those
with dependents (dep) (Table 3, column 5). The fact that
other MRS figures are insignificant may partly be attrib-
utable to the size of sample. Wald test results (Table 3,
column 7) indicate statistically significant differences in
MRS between other stakeholder groups and patients (5%
level). The results presented in Table 4 suggest MRS for
prioritizing perfect over favourable tissue matches is
lower amongst carers than patients (1 year MRS = insig-
nificant vs. 1.41; 5 year MRS = insignificant vs. 0.28);
and lower for prioritizing favourable over non-
favourable matches (1 year MRS = insignificant vs 4.23;
5 year MRS = insignificant vs. 0.85). Moreover, Waldtests (Table 3, column 7) show carers’ preference for pri-
oritizing those with dependents is less than patients’
(1 year MRS = insignificant vs. 1.43; 5 year MRS = insig-
nificant vs. 0.29). Wald tests also show that carers
prioritize those with moderate not severe diseases pre-
dominantly affecting life expectancy (dis2) more than do
patients (1 year MRS = 16.79 vs. 15.32; 5 year MRS =
3.36 vs. 3.06).
Donor response analysis was also compromised by a
smaller sample size (n=48). This may explain why MRS
(MRS for 1 and 5 years in Table 4) is only significant for 2
variables (‘dis2’ and ‘ill2’). Once again, Wald tests (Table 3,
column 4) suggest that donors value tissue match (tiss)
less than patients (1 year MRS = insignificant vs. 1.41;
5 year MRS = insignificant vs. 0.28) for perfect not
favourable matches, and also value favourable not non-
favourable matches less (1 year MRS = insignificant vs.
4.23; 5 year MRS = insignificant vs. 0.85). Similar to carers,
Wald tests (Table 3, column 4) indicate donors value pri-
oritizing dependents (dep) less than patients do (1 year
MRS = insignificant vs. 1.43; 5 year MRS = insignificant
vs. 0.29). They also suggest that donors value prioritizing
the young (age) less than patients (1 year MRS = insignifi-
cant vs. 0.16; 5 year MRS = insignificant vs. 0.03). Donors,
in contrast to carers, prioritize those with moderate rather
than severe co-morbidities predominantly affecting life ex-
pectancy less than do patients (1 year MRS = 11.54 vs.
15.32; 5 years MRS = 2.31 vs. 3.06). Wald tests do not in-
dicate other differences.
Analysis of healthcare professionals’ responses indi-
cates MRS is significant for 6/7 variables (Tables 3 and
4) and Wald tests (Table 3, column 7) suggest healthcare
professionals’ preferences differ from those of patients
for 5/7 variables. Professionals value prioritizing those
with better tissue matches ‘tiss’ less than do patients
(1 year MRS = 1.27 vs. 1.41; 5 year MRS = 0.25 vs. 0.28)
for perfect not favourable matches, and prioritize favou-
rable vs. non-favourable matches less (1 year MRS = 3.82
vs. 4.23 ; 5 year MRS = 0.76 vs. 0.85). Wald tests also
indicate healthcare professionals prioritize those with
dependents (dep) more (1 year MRS = 1.56 vs. 1.43; 5 year
MRS = 0.31 vs. 0.29), and younger recipients (age) more
(1 year MRS = 0.48 vs. 016; 5 year MRS = 0.10 vs. 0.03).
They would also prioritize (dis1) those with no vs. moder-
ate diseases affecting life expectancy whereas patients
would not (1 year MRS = 4.50 vs insignificant; 5 year
MRS = 0.90 vs. insignificant). Similarly, healthcare profes-
sionals also prioritized (dis2) those with moderate rather
than severe diseases affecting life expectancy more than
patients did (1 year MRS = 19.42 vs. 15.32; 5 year
MRS = 3.88 vs 3.06). However, there was no evidence that
healthcare professionals would prioritize recipients with
co-morbid diseases predominantly affecting quality of life
differently from patients (Wald tests for ill1 and ill2 are
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fessionals exhibit statistically significant differences to
patients for 5/7 variables suggests that, if healthcare pro-
fessionals’ preferences were to prevail in transplant deci-
sion-making, this could result in transplant allocation
decisions which inadequately reflect patient preferences.
Measures of ‘goodness of fit’ for model 2 indicate
62.09% actual values are predicted by the model, and
McFadden's R2 = 0.133. A likelihood ratio test for the
significance of the dummy variables has λ = 35.83, whichTable 5 Model 2: Patient values vs. those of ethnic minorities
Variable Coefficient for non-
ethnic minorities
MRS for non-e
minorities
Wait .0451* 1
Tiss .0698* 1.54*
(1.19 / 1.90)
Dep .0595* 1.32*
(1.05 / 1.59)
Age .0071* 0.16*
(0.12 / 0.20)
dis1 .0039 0.09
(−0.98 / 1.15)
dis2 .7158* 15.86*
(13.87 / 17.85)
ill1 -.1085* −2.40*
(−1.06 / -3.74)
ill2 .1773* 3.93*
(2.82 / 5.03)
Intercepts .1269*
Variable Non-ethnic minorities
trade-off between
variable & 1 year wait
Non-ethnic mi
trade-off betw
variable & 5 y
Prioritizing perfect not
favourable tissue matches
1.54* 0.31*
(1.19 / 1.90) (0.24 / 0.38)
Prioritizing favourable not
non- favourable tissue
matches.
4.64* 0.93*
(3.57 / 5.70) (0.71 / 1.14)
Prioritizing a recipient with
dependents – per extra
dependent
1.32* 0.26*
(1.05 / 1.59) (0.21 / 0.32)
prioritizing a younger
recipient – per year younger
0.16* 0.03*
(0.12 / 0.20) (0.02 / 0.04)
Prioritizing those with no not
moderate diseases affecting
life expectancy
0.09 0.02
(−0.98 / 1.15) (−0.20 / 0.23)
Prioritizing those with
moderate not severe
diseases affecting life
expectancy
15.86* 3.17*
(13.87 / 17.85) (2.77 / 3.57)
Prioritizing those with no not
moderate diseases affecting
QoL
−2.40* −0.48*
(−1.06 / -3.74) (−0.21 / -0.75)
Prioritizing those with
moderate not severe
diseases affecting QoL
3.93* 0.79*
(2.82 / 5.03) (0.56 / 1.01)
*: Significant at the 5% level; Figures in parentheses indicate 95% confidence interv
Includes MRS expressed in terms of utility value of other attributes expressed in tercompares with a critical value for 9 degrees of freedom
of 16.92, so the dummy variables are jointly significant.
Table 5 compares ethnic minority and white majority
patients (model 2). Coefficients are as defined in Table 1,
and MRS specified in Additional file 4. Overall 3 dummy
variables (tiss, dep and dis2) were significant, but Wald
tests (Table 5, column 6) suggest more differences includ-
ing the following. Ethnic minorities do not prioritize reci-
pients with better tissue matches (tiss) but the majority
population do (1 year MRS = insignificant vs. 1.54; 5 years(96 out of 908 are ethnic minorities)
thnic Coefficient for
dummy variables for
ethnic minorities
MRS for ethnic
minority patients
Wald
test p-
values
-.0061 1
-.0630** 0.17 p<0.0001
(−0.82 / 1.17)
.0351* 2.42* p=0.2755
(1.40 / 3.44)
-.0011 0.15* p=0.0024
(0.03 / 0.27)
-.0398 −0.92 p=0.6014
(−4.41 / 2.57)
-.3153** 10.25* p<0.0001
(4.96 / 15.53)
-.0903 −5.08* p=0.9050
(−0.83 / -9.33)
.0647 6.19* p=0.2558
(2.51 / 9.88)
-.0510
norities
een
ear wait
Ethnic minority trade-
off between variable
& 1 year wait
Ethnic minority trade-
off between variable
& 5 year wait
0.17 0.35
(−0.82 / 1.17) (−0.16/ 0.23)
0.52 0.10
(−2.46 / 3.50) (−0.49 / 0.70)
2.42** 0.48*
(1.40 / 3.44) (0.28 / 0.69)
0.15* 0.03*
(0.03 / 0.27) (0.01 / 0.05)
−0.92 −0.18
(−4.41 / 2.57) (−0.88 / 0.51)
10.25* 2.05*
(4.96 / 15.53) (0.99 / 3.11)
−5.08* −1.02*
(−0.83 / -9.33) (−0.17 / -1.87)
6.19* 1.24*
(2.51 / 9.88) (0.50 / 1.98)
als for point estimates.
ms of trade-off with 1 year and 5 year waiting time.
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favourable matches). For favourable, rather than non-
favourable, matches only white majority patients valued
favourable matches significantly (1 year MRS = insignifi-
cant vs. 4.64; 5 years MRS = insignificant vs. 0.93). This is
perhaps because ethnic minorities are disadvantaged if a
close tissue match is required, due to a lack of ethnic mi-
nority donors. Wald test results indicate that MRS for pri-
oritizing younger (age) rather than older recipients differs
only marginally between ethnic minority and other
patients (1 year MRS = 0.15 vs. 0.16; 5 year MRS = 0.03
vs. 0.03). Finally, Wald tests also suggest ethnic minority
patients value prioritizing recipients with moderate vs. se-
vere diseases (dis2) affecting life expectancy less than
other patients (1 year MRS = 10.25 vs. 15.86; 5 year
MRS = 2.05 vs 3.17). Once again, this is perhaps linked to
the higher prevalence of severe diseases / co-morbidities
predominantly affecting life expectancy amongst ethnic
minorities. Wald tests did not indicate that valuation of
other attributes varied by ethnicity.
Discussion
This study is unique because, although DCEs have been
used in relation to liver transplantation to identify public
[17] and patient [16] preferences, this is the first applica-
tion of DCEs exclusively relating to prioritizing renal
transplants. Moreover, the detailed comparisons between
stakeholder respondent groups are unprecedented.
Usually when DCEs are used to address healthcare
issues they look at patient preferences. In contrast our
study compares preferences across a range of different
stakeholder groups, deploying a new approach that had
not been deployed in kidney transplant research before
this project. The DCE approach allows for comparison
of preferences between groups, and assessment of
whether differences are statistically significant. Import-
antly, our findings indicate when stakeholder groups’
preferences differ. This means that DCE studies that
only elicit preferences for one group may fail to take into
account preference heterogeneity. Establishing whether
preferences vary between stakeholder groups (especially
patients and healthcare professionals) is important for
policy and practice.
Although DCEs are increasingly used in health services
research, one potential limitation can be the sensitivity of
results to the choice of attributes presented, since it is only
possible to indicate trade-offs in relation to the actual
attributes selected. Therefore, it is essential to consult a
wide range of opinion during the attribute selection
process, including patients and professionals, before de-
ciding upon which attributes to include. The present study
included such a process. Constructing a robust DCE also
requires that the choice of attributes has emerged from a
thorough pilot exercise. In the present study, a great dealof time was invested in piloting the questionnaire to try to
ensure that the range of attributes and levels identified for
inclusion in our DCE questionnaires was appropriate.
Our analysis of patient responses showed that respon-
dents valued prioritizing patients with closer tissue
matches, but also valued other factors significantly includ-
ing prioritizing: long waiters; those with child or adult
dependents; and younger recipients. Furthermore, in
terms of co-morbidities affecting life expectancy, indivi-
duals with moderate diseases were prioritized over those
with severe diseases, but those with moderate diseases
were not prioritized over those with no such disease. In
terms of diseases predominantly affecting quality of life
(rather than life expectancy) patients prioritized recipients
with moderate rather than no disease, and those with
moderate rather than severe disease. However, for ethnic
minority patients our findings demonstrate that, unlike
other patients, this group did not value tissue match sig-
nificantly. They also valued prioritizing those with severe
rather than moderate disease affecting life expectancy less
than other patients did.
We are also able to report on the preferences of carers.
Although the sample was small (n = 41), it was sufficient
to establish some statistically significant differences
when compared with patients’ responses, but probably
insufficient for all differences in preferences between
carers and patients to be demonstrated in a statistically
significant manner. The number of carer responses
obtained via our request in the publication ‘Kidney Life’
was probably limited by the fact that this publication is
read more by patients than those who care for renal
patients. An alternative strategy would have been to ask
patient respondents to supply the name and address of
their carer (if applicable) to approach. However, despite
the fact we only had 41 carer responses, this data was
sufficient to establish that some carer preferences differ
significantly from those of patients. In contrast to
patients, carers did not value prioritizing those with bet-
ter tissue matches or those with dependents. But, they
did value prioritizing those with moderate not severe
diseases affecting life expectancy more than patients.
Whilst it is interesting that carer preferences differed
from those of patients, patient preferences are clearly
more important in terms of decisions on kidney trans-
plant criteria.
In terms of donor preferences, the sample size (n = 48
donor families / live donors) was sufficient to discern that
some preferences differed in a statistically significant man-
ner compared to those of patients. Our findings indicate
that donors, like ethnic minority patients, did not value
prioritizing better tissue matches significantly. They also
valued transplants to those with dependents, younger reci-
pients, and those with moderate rather than severe disease
affecting life expectancy more than patients did. Donor
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donors transplantation programmes cannot continue. It
might have been possible to obtain a larger sample of this
stakeholder group if we had targeted people on the organ
donor register as well as actual donor families and live
donors, this would have increased statistical power thereby
potentially allowing us to establish other statistically sig-
nificant differences in preferences.
The number of responses from healthcare professionals
(n = 113) was more than adequate to discern preferences
for the group as a whole. In terms of overall preferences,
healthcare professionals’ preferences differed from those of
patients in that professionals valued prioritizing better tis-
sue matches less than patients did, but valued prioritizing
those with dependents more. They also prioritized those
with no rather than moderate diseases predominantly
affecting life expectancy whereas patients would not; and
prioritised those with severe rather than moderate diseases
affecting quality of life more than patients. Unfortunately,
the sub-sample of renal physicians (as opposed to health-
care professionals more generally) was not large enough to
establish how their preferences might differ from those of
patients. Given that it is renal physicians who are involved
in decisions about allocating kidneys, more detailed infor-
mation on the preferences of this important group of
healthcare professionals would have been useful.
The difference between patients and healthcare profes-
sionals in prioritizing recipients with diseases affecting
quality of life may be rationalized if patient preferences are
biased due to many individuals in the patient group having
moderate disease. However, it is less clear why health-
care professionals place less emphasis upon closeness of
donor–recipient tissue match. In this respect, our findings
indicate that if transplant allocation decisions and policies
are based solely on healthcare professionals’ own prefer-
ences this may conflict with patient wishes.
In terms of relevance for transplant policy, our DCE
study was not intended to identify specific individuals
“who should be prioritized for renal transplantation”. Ra-
ther, it aimed to identify certain potential characteristics
of kidney recipients characteristics which different stake-
holder groups consider should be prioritized, and there-
fore suggest potential transplant recipient groups who
ought to be made a higher or lower priority for trans-
plantation. It is reassuring that our findings are broadly
supportive of the 2006 revisions to UK kidney transplant
policy in terms of prioritizing long waiters and young
adults. However, although our analysis shows that this can
be justified, it also suggests that other criteria (i.e. priori-
tizing those with dependents) ought to be considered.
Our findings can be considered alongside a number of
earlier non-DCE studies. An Australian-based renal study
unlike ours adopted a general public perspective [10].
Respondents were found to prioritize long waiters and theyoung, but had a split verdict over whether to prioritize
those with children. Similarly, renal research into African
Americans’ preferences [9] indicates that kidney allocation
based upon HLA matching is considered unfair. However,
at the same time, African Americans did not want to re-
ceive organs with lower survival rates; note since this
paper was published (1997) graft survival for poorer
matches has improved. More recently, a 2005 Glasgow
renal study [11] has used a non-DCE scenario approach to
consider allocation of deceased donor kidneys for trans-
plantation. Interestingly, certain findings from this re-
search conflict with our results (i.e. tissue matching was
not a major allocation criterion) although, like our find-
ings, the researchers reported that emphasis was placed
on prioritizing long-waiters (albeit defined by time on
dialysis, not on waiting lists). One DCE study, a 2010
Canadian article on patients with chronic kidney disease
[19] has reported that respondents preferred to prioritize
kidney transplants on the basis of a ‘best match’ rather
than ‘first come, first served.’ However, in contrast to our
study, this particular DCE considered a wide range of
attributes relating to CKD in general (including organ pro-
curement and the organization of care) and as such could
provide only a very limited indication of preferences for
kidney transplant allocation. The DCE included only one
attribute relating to kidney transplants (“How should
deceased donor kidneys for transplantation be allocated
for transplantation”) with just two possible levels ‘best
match’, or ‘first come, first served.’ Moreover, unlike our
DCE study which furnished respondents with information
on the likelihood of kidney transplants being successful
for non-favourable matches, it is unclear whether similar
information was provided in the Canadian study to ensure
fully informed responses.
Interestingly, a recent article which discusses new allo-
cation concepts [28] emphasises efficiency criteria related
to maximising health gains (i.e. getting the most life years
from organs available for transplant). Whilst maximising
life years or Quality Adjusted Life Years (QALYs) may be a
legitimate transplant policy objective (and is supported by
our findings in the sense that respondents value prioritiz-
ing younger patients in our DCE analysis), it is clear from
our results that stakeholders also value equity considera-
tions (i.e. avoiding patients having to face excessive waiting
times). This is something which comes out strongly in our
analysis of different stakeholders’ priorities, but would be
neglected in an approach which focuses upon maximising
health gains. Furthermore, the findings reported here and
in our earlier analysis [18] indicate that, although both
time spent waiting and the quality of tissue match between
donor and recipient are of importance to healthcare wor-
kers and patients, amongst ethnic minority patients close-
ness of tissue match is not a significant determinant of
patient preferences.
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in our earlier analysis [18], suggest that both time spent
waiting and the quality of tissue match between donor
and recipient are of importance to healthcare workers
and to non-ethnic minority patients, but that amongst
ethnic minority patients closeness of tissue match is not
a significant determinant of patient preferences. As
DCEs can be used in order to quantify key stakeholders’
willingness to ‘trade-off ’ between conflicting transplant
allocation criteria, data from the present study could in
principle be used to underpin kidney transplant alloca-
tion policy thereby increasing transparency [29]. For ex-
ample, if the weightings obtained were to be used for
informing organ allocation decisions then, rather like the
MELD scores which underpin Liver transplant policy in
the USA, this would increase transparency. However,
such an approach would sideline other valid evidence
[3,9-11,28,30] resulting in a more mechanistic process.
In our view therefore such a mechanistic approach is
inappropriate.
The United Network for Organ Sharing (UNOS) pol-
icy takes into account the length of time spent on the
waiting list; whether the potential organ candidate is a
child; body size of both donor and candidate; tissue
match between donor and candidate; blood type; and
blood antibody levels. Although we wanted to avoid
being too prescriptive about how either UK or USA
transplant policy should be changed, in the light of our
findings it is clear that changes to USA transplant policy
in 2003, and UK transplant policy in 2006, have already
led to a shift away from considerable reliance upon
transplanting on the basis of a close HLA tissue match
between donor and recipient. Changes to USA policy
(7th May 2003) involved an elimination of HLA-B simi-
larity as a transplant allocation criterion [30]. This was
because improvements to medications used to prevent
transplant rejection reduced the benefit that previously
had been associated with HLA-B matching (which had
discriminated [perhaps unintentionally] against ethnic
minorities). The current US policy has been suitably
characterized as one of “Equal opportunity supplemen-
ted by fair innings” [31] and reported to have “improved
access to transplantation for all minority groups” in the
USA [28]. The first 6 year follow-up reported that the
2003 change in policy “has improved access to trans-
plantation for all minority groups and has not been asso-
ciated with a decrease in 2 year graft survival” [30].
Decreased emphasis on close tissue matching and more
emphasis on prioritizing long waiters is similarly
reported to have reduced the extent to which ethnic mi-
nority groups are disadvantaged in the UK [18].
However, our finding that UK ethnic minority patients
do not value prioritizing recipients on the basis of close-
ness of tissue match indicates that there may be scope inthe USA and the UK to consider further reducing the re-
liance upon donor-recipient HLA matching when allo-
cating kidneys, without triggering a reduction in overall
rates of graft survival if rates of graft survival continue
to improve anyway. Such a policy shift would mean that
the preferences of ethnic minority patients are better
accommodated by transplant policy, alongside the pre-
ferences of other patients. More recently in 2011 [32] a
USA concept document has been launched relating to
kidney transplantation which advocates prioritizing the
young because they have greater capacity to benefit. A
problem with the approach is that whilst it might help
maximize overall life expectancy from available trans-
plants it discriminates against the old [32]. However,
children are normally treated as an absolute priority, and
our DCE analysis shows nothing to suggest otherwise.
Indeed our findings indicate that this preference extends
to young adults, which is not a completely new finding
but important to make clear.
A further step in extending the differentiation between
patients on the transplant list would be to include social
and medical factors as well as age. The issue of whether
an allocation policy should treat people differently, either
because they are felt to be more ‘deserving’ or because
allocating organs to some people and not others will give
longer graft survival overall, is part of the equality/effi-
ciency debate [3,18]. In this respect our study makes an
important contribution. Our pilot study ruled out a pre-
ference for social factors such as prioritizing those in
employment. Our main DCE findings did show a prefer-
ence for allocation according to some co-morbidities
affecting life expectancy or quality of life. Our research
also indicates that a measure of ‘social value’ (whether
recipients have dependents) was valued by UK respon-
dents. So, when transplant policy is re-appraised, consid-
eration might be given to this additional criterion,
though it is equally possible that the transplant policy
group might not wish to include it for practical or eth-
ical reasons. In either case, the use of DCEs to define
and quantify stakeholders’ preferences can provide a
valid structure for the decision making process.Conclusions
The findings of this study raise significant issues around
transplant allocation to those from ethnic minority
groups (who unlike other patients do not favour alloca-
tion on the basis of a close tissue match between donor
and recipient; and also value prioritizing those with se-
vere rather than moderate disease affecting life expect-
ancy less than other patients do). Our findings also
highlight important differences in preferences between
healthcare professionals and patients (healthcare profes-
sionals prioritize better tissue matches less than patients
Clark et al. BMC Nephrology 2012, 13:152 Page 13 of 14
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Professionals would also prioritize those with no rather
than moderate co-morbidities affecting life expectancy
(more than patients), and would prioritize severe rather
than moderate co-morbidities affecting quality of life
more than patients would). Whilst respondents in our
study did not think employment status should be a fac-
tor in kidney allocation, having dependents was valued.
These findings ought to be considered when UK renal
transplant policy is next re-appraised. This research also
adds to the growing international literature relating to
transplant allocation policy.
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